These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 3049804

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH.
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [Abstract] [Full Text] [Related]

  • 4. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M, Bukhari Z, Sachs DH.
    Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.
    Chester CH, Sykes M, Sachs DH.
    Bone Marrow Transplant; 1989 Mar; 4(2):195-200. PubMed ID: 2650790
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes.
    Hayashi S, Hsieh M, Peranteau WH, Ashizuka S, Flake AW.
    Exp Hematol; 2004 Mar; 32(3):290-9. PubMed ID: 15003315
    [Abstract] [Full Text] [Related]

  • 12. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Mar; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 13. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL, Atasoylu AA.
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [Abstract] [Full Text] [Related]

  • 14. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 15. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, Kawakami M, Masuda T, Aozasa K, Kawase I, Ogawa H.
    Exp Hematol; 2008 Sep 15; 36(9):1216-25. PubMed ID: 18599183
    [Abstract] [Full Text] [Related]

  • 16. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 Sep 15; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 17. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 15; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 18. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM, Gorechlad J, Larsen CP, Waller EK.
    Biol Blood Marrow Transplant; 2006 Dec 15; 12(12):1239-49. PubMed ID: 17162205
    [Abstract] [Full Text] [Related]

  • 19. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
    Shizuru JA, Jerabek L, Edwards CT, Weissman IL.
    Biol Blood Marrow Transplant; 1996 Feb 15; 2(1):3-14. PubMed ID: 9078349
    [Abstract] [Full Text] [Related]

  • 20. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S, Kamisaku H, Sado T.
    Bone Marrow Transplant; 1995 Oct 15; 16(4):603-9. PubMed ID: 8528179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.